期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 10, 期 2, 页码 168-174出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.8b00535
关键词
Flavivirus; macrocyclic peptides; protease inhibitors; noncanonical amino acids; display screening
资金
- Alexander von Humboldt Foundation
- Australian Research Council
- Laureate Fellowship
- CREST for Molecular Technologies, JST
- JSPS KAKENHI [16H06444, 26220204]
- Deutsche Forschungsgemeinschaft [KL-1356/3-2]
- Grants-in-Aid for Scientific Research [16H06444, 26220204] Funding Source: KAKEN
The Zika virus presents a major public health concern due to severe fetal neurological disorders associated with infections in pregnant women. In addition to vaccine development, the discovery of selective antiviral drugs is essential to combat future epidemic Zika virus outbreaks. The Zika virus NS2B-NS3 protease, which performs replication-critical cleavages of the viral polyprotein, is a promising drug target. We report the first macrocyclic peptide-based inhibitors of the NS2B-NS3 protease, discovered de novo through in vitro display screening of a genetically reprogrammed library including noncanonical residues. Six compounds were selected, resynthesized, and isolated, all of which displayed affinities in the low nanomolar concentration range. Five compounds showed significant protease inhibition. Two of these were validated as hits with submicromolar inhibition constants and selectivity toward Zika over the related proteases from dengue and West Nile viruses. The compounds were characterized as noncompetitive inhibitors, suggesting allosteric inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据